Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra by Intra-articular Injection for Psoriatic Arthritis
NCT06522035Phase 1Terminated
- Sponsor
- Enlivex Therapeutics
- Start
- Aug 2024
- Primary completion
- Oct 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Allocetra in psoriatic arthritis (PsA) (2 arms), sponsored by Enlivex Therapeutics. Started Aug 2024; status: terminated.
02
Drugs
Allocetra
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06522035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522035.